BioCryst Pharmaceuticals | BCRX - Cash And Equivalent


BioCryst Pharmaceuticals reported $154.97M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Chugai Pharma JPY 426.6B 29.83B Dec/2025
Daiichi Sankyo JPY 449.81B 92.35B Mar/2026
DBV Technologies USD 174.9M 54.3M Jun/2026
Enanta Pharmaceuticals USD 37.44M 5.14M Dec/2025
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Novavax USD 191.46M 36.9M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026